Breaking barriers in HIV treatment: the game-changing impact of lenacapavir

Authors

  • Sameen Mukhtar Department of Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan
  • Muhammad Haris Department of Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20233872

Keywords:

HIV, HIV/AIDS, immunodeficiency

Abstract

HIV is a lentivirus that selectively targets and infects CD4 cells, which are integral to the immune system. Through viral integration and replication, infected cells are gradually destroyed, leading to a weakened immune system and an increased susceptibility to illnesses. The HIV epidemic has resulted in approximately 40.1 million deaths and 84.2 million infections to date, with 38.4 million individuals living with HIV as of the end of 2021. The estimated global prevalence of HIV in adults aged 15 to 49 is 0.7%.

Metrics

Metrics Loading ...

References

WebMD. How to Treat HIV, 2023. Available at: https://www.webmd.com/hivaids/understandingaids-hiv-treatment#091e9c5e80008962-1-3. Accessed on 01 October 2023.

Sunlenca. SUNLENCA® Was Granted FDA Breakthrough Therapy Designation and Has a Novel MOA1,2, 2023. Available at: https://www. sunlencahcp.com/howsunlencaworks/first-in-class-moa/. Accessed on 01 October 2023.

Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17(1):15-21.

Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigatoet alrs. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386(19):1793-803.

REUTERS. U.S. FDA approves Gilead's long-acting HIV drug Sunlenca, 2023. Available at: https://www.reuters.com/business/healthcarlongacting-hiv-drug-sunlenca-2022-12-22/. Accessed on 01 October 2023.

USFDA. FDA Approves New HIV Drug for Adults with Limited Treatment Options, 2022. Available at: https://www.fda.gov/newsevents/presslimitedtreatment-options. Accessed on 01 October 2023.

Downloads

Published

2023-12-22

Issue

Section

Letter to the Editor